Pirtobrutinib

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more.

In this video, Jakub Svoboda, MD, discusses an update on pirtobrutinib, which was recently approved for relapsing mantle cell lymphoma that has been previously treated with Bruton tyrosine kinase inhibitors.

Pirtobrutinib appeared effective among a cohort of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results published in The New England Journal of Medicine.

In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.